Sen. Ron Johnson (R-Wisconsin) has sent yet another letter to the heads of all US public health agencies seeking answers to questions regarding the federal government response to Covid-19. Johnson sent his letter to the Secretary of the Department of […]
The following is an excerpt from Becker’s Healthcare Hospital Review. Immunology experts have not concluded that more COVID-19 boosters are necessary despite Pfizer and Moderna’s efforts to promote the shots, Kaiser Health News reported March 21. On March 13, Pfizer CEO Albert
Experts: skeptical of more Covid-19 boosters despite drugmakers’ efforts Read More »
The following is an excerpt from MedPage. Moderna’s two-dose Covid-19 vaccine regimen for the youngest children was safe and met its primary immunogenicity endpoint, the manufacturer announced on Wednesday. An interim analysis of the phase II/III KidCOVE study found that two
Moderna to seek FDA authorization for lower-dose Covid-19 vaccine for children under 6 Read More »
A federal district court has issued a preliminary injunction, effectively putting a temporary halt to the District of Columbia’s controversial Minor Consent for Vaccinations Act of 2020. This act allowed children 11 years of age and older to consent to
(READ) ‘Major legal victory’ for child advocacy groups re: DC minor consent law Read More »
The following is an excerpt from Becker’s Healthcare – Hospital CFO Report. “Right now, we don’t have enough money for fourth doses, if they’re called for,” Jeff Zients, White House Covid-19 response coordinator, said on a forthcoming episode of the
(READ) White House says it has no money to buy 4th doses of Covid-19 vaccine Read More »
New Hampshire’s Republican-controlled House has passed a bill that would allow pharmacists to dispense the malaria and anti-Covid medicine Ivermectin as a standard order, meaning over-the-counter without a doctor’s prescription. Similar bills are also working their way through state legislatures in Oklahoma,
(READ) New Hampshire approves bill to make Ivermectin an over-the-counter drug Read More »
The biggest new hope for a blockbuster drug to cure Alzheimer’s has been mired in controversy ever since it went to market. Critics say it’s a sign of declining standards and conflicts of interest at the FDA. And now, the
FDA Adviser Dr. Caleb Alexander of John’s Hopkins talks about Aducanumab/Aduhelm: a groundbreaking Alzheimer’s treatment sent to market in one of the most controversial FDA approvals ever.
